Q-omics provides the consensus-scored ZNF654 profile across patient tissues and cancer cell-line models. ZNF654 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF654 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF654 RNA expression shows 21,498 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where ZNF654 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF654 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF654 survival associations across molecular data types. ZNF654 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF654 RNA expression–survival associations across cancer types. High ZNF654 expression shows unfavorable associations in KICH, PAAD and ACC, but favorable associations in KIRC, UCS and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF654 RNA expression.
This table summarizes ZNF654 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF654. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF654 shows lower tumor expression in THCA, LUSC, COAD, LUAD and READ and higher tumor expression in KIRC. The THCA box plot shows higher ZNF654 RNA expression in normal versus tumor tissue (log2 FC = −0.701, t-test p < 0.001).
This table shows molecular features associated with ZNF654 in patient tissues and cancer cell lines. In patient samples, ZNF654 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF654 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
